Expertise in
1
conditions

Marc-steffen Raab

Heidelberg, BW, DE 
Expertise in
1
conditions
Heidelberg, BW, DE 

Overview

Marc-steffen Raab practices practicing medicine in Heidelberg, Germany.

Raab is highly rated in 1 condition, according to our data. Their clinical expertise encompasses Multiple Myeloma, Smoldering Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Primary Amyloidosis, and Bone Marrow Transplant.

They are actively involved in clinical research, co-authoring 35 peer reviewed articles and participating in 2 clinical trials.

Locations

Heidelberg, BW, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 1a/1b Multicenter, Single-Arm, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Activity of Oral ACY-241 Alone and in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Relapsed-and-Refractory Multiple Myeloma
A Phase 1a/1b Multicenter, Single-Arm, Open-Label, Dose-Escalation Study to Determine the Maximum Tolerated Dose, Safety, and Preliminary Activity of Oral ACY-241 Alone and in Combination With Pomalidomide and Low-Dose Dexamethasone in Patients With Relapsed or Relapsed-and-Refractory Multiple Myeloma
Enrollment Status: Terminated
Publish Date: July 09, 2024
Intervention Type: Drug
Study Drugs: ACY-241, Pomalidomide, Dexamethasone
Study Phase: Phase 1
A Phase I Open-Label Dose Escalation Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care Chemotherapy for the Treatment of Multiple Myeloma
A Phase I Open-Label Dose Escalation Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care Chemotherapy for the Treatment of Multiple Myeloma
Enrollment Status: Completed
Publish Date: July 10, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 1 Less Clinical Trial

35 Total Publications

MCL-1 inhibition triggers a largely reversible cardiac stress signature in a humanised mouse model.
MCL-1 inhibition triggers a largely reversible cardiac stress signature in a humanised mouse model.
Journal: British journal of pharmacology
Published: March 16, 2026

Frequently Asked Questions about Marc-steffen Raab

Is Marc-steffen Raab a top-rated expert for Multiple Myeloma?

MediFind is an objective health platform that identifies experts based on real-world data. Marc-steffen Raab is classified as an Distinguished expert for Multiple Myeloma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Marc-steffen Raab participate in research or clinical trials?

Yes. Marc-steffen Raab has published 35 articles and abstracts on conditions like Multiple Myeloma. You can view a list of Marc-steffen Raab's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Raab's expertise for a condition
ConditionClose
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile